



EXHIBIT C

Redline Version of Amended Claims

9. [A] The method for detecting [novel lipoprotein concerning arteriosclerotic lesion] LDL and denatured LDL described in Claim 2 using an antihuman fibrinogen antibody and an immune reaction detecting reagent such as an antihuman ApoB antibody and the like labeled with a labeling substance typically including an enzyme.

10. [A] The method for detecting [novel lipoprotein concerning arteriosclerotic lesion] LDL and denatured LDL described in Claim 2 using an antihuman fibronectin antibody and an immune reaction detecting reagent such as an antihuman ApoB antibody and the like labeled with a labeling substance typically including an enzyme.

11. A monoclonal antibody for use in the detecting method according to Claim 10 produced from a hybridoma obtained by fusing a mouse [myeloma] mayeloma cell with a spleen cell from mammals immunized with a LDL/fibronectin [complex] complex, wherein the antibody does not react with native fibronectin and ApoB (native and denatured ApoB) and specifically recognizes a LDL/fibronectin complex.